0001104659-23-096669.txt : 20230830 0001104659-23-096669.hdr.sgml : 20230830 20230830062101 ACCESSION NUMBER: 0001104659-23-096669 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230830 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230830 DATE AS OF CHANGE: 20230830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 231223660 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 8-K 1 tm2325118d1_8k.htm FORM 8-K
0001649989 false 0001649989 2023-08-30 2023-08-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 30, 2023

 

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37759 38-3982704
(State or other jurisdiction
of incorporation) 		(Commission File Number) (IRS Employer Identification No.)

 

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey

 08830
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (609) 619-3990

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock   OTLK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On August 30, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter to the Company’s biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

 

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.   Description
99.1   Press Release dated August 30, 2023.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Outlook Therapeutics, Inc.
   
Date: August 30, 2023 By: /s/ Lawrence A. Kenyon
    Lawrence A. Kenyon
    Chief Financial Officer

 

 

 EX-99.1 2 tm2325118d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

 

FDA issues Complete Response Letter (CRL) for ONS-5010 BLA based on CMC and need for further confirmatory clinical evidence

 

Outlook Therapeutics working with FDA to address the Agency’s issues

 

Company to host conference call and webcast, today, August 30 at 8:30 AM ET

 

ISELIN, N.J., August 30, 2023 — (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the U.S. Food and Drug Administration (FDA) has issued a CRL to the Company’s BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoints, the Agency concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

 

“We continue to believe in the public health need to provide the retina community with an FDA-approved bevacizumab treatment option for wet AMD. We will request a formal meeting as soon as possible with the FDA to further understand the BLA deficiencies and how best to resolve them. Following this meeting with the FDA, the Company will be able to discuss next steps and the expected timing for resolution,” said Russell Trenary, President and CEO of Outlook Therapeutics.

 

Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital and an Outlook Therapeutics Board member, commented, “The retina community needs an FDA-approved ophthalmic bevacizumab to deliver an alternative targeted on-label treatment for patients with wet AMD.”

 

Investor Conference Call and Webcast

 

Outlook Therapeutics management will host a corporate update conference call and webcast today, August 30, 2023 at 8:30 AM ET.

 

Interested participants and investors may access the conference call by dialing (877) 407-8291 (domestic) or (201) 689-8345 (international). The live webcast will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com, and will be archived there for 90 days.

 

 

 

 

About ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

 

ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no FDA-approved ophthalmic formulations of bevacizumab are available currently, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacies—products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010 would provide an FDA-approved option for physicians that currently have no choice but to prescribe unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for the treatment of wet AMD.

 

Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab-vikg to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.

 

About Outlook Therapeutics, Inc.

 

Outlook Therapeutics is a biopharmaceutical company working to achieve FDA approval for the launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with an initial PDUFA goal date of August 29, 2023; FDA did not approve the BLA during this review cycle and the Company is working with the FDA to address the issues that have been raised so that the BLA may be re-submitted. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, Outlook Therapeutics and AmerisourceBergen entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States. For more information, please visit www.outlooktherapeutics.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “may,” “might,” “intend,” “potential,” “predict,” “should,” or “will,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about ONS-5010’s potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, expectations concerning our ability to remediate or otherwise resolve deficiencies identified in the CRL, expectations concerning a formal meeting with the FDA and the outcome thereof, our plans to discuss next steps and timing for resolution of deficiencies identified in the CRL, expectations concerning decisions of regulatory bodies, including the FDA, and the timing thereof, expectations concerning our relationship with AmerisourceBergen and the benefits and potential expansion thereof and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of the expected follow up meeting with the FDA, the content and timing of decisions by the FDA, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the “SEC”), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2022 as supplemented by the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, in each case as filed with the SEC and future quarterly reports we file with the SEC, which include the uncertainty of future impacts related to macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine,  high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

 

 

 

 

CONTACTS:

 

Media Inquiries:

Harriet Ullman

Vice President

LaVoieHealthScience

T: 617.429.5475

hullman@lavoiehealthscience.com

 

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247

OTLK@jtcir.com

 

# # #

 

 

 

 EX-101.SCH 3 otlk-20230830.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 otlk-20230830_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Series A Warrants EX-101.PRE 5 otlk-20230830_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2325118d1_ex99-1img01.jpg GRAPHIC begin 644 tm2325118d1_ex99-1img01.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 30, 2023
Entity File Number 001-37759
Entity Registrant Name Outlook Therapeutics, Inc.
Entity Central Index Key 0001649989
Entity Tax Identification Number 38-3982704
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 485 Route 1 South
Entity Address, Address Line Two Building F
Entity Address, Address Line Three Suite 320
Entity Address, City or Town Iselin
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08830
City Area Code 609
Local Phone Number 619-3990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OTLK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2325118d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001649989 2023-08-30 2023-08-30 iso4217:USD shares iso4217:USD shares 0001649989 false 8-K 2023-08-30 Outlook Therapeutics, Inc. DE 001-37759 38-3982704 485 Route 1 South Building F Suite 320 Iselin NJ 08830 609 619-3990 false false false false Common Stock OTLK NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://outlooktherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2325118d1_8k.htm otlk-20230830.xsd otlk-20230830_lab.xml otlk-20230830_pre.xml tm2325118d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2325118d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2325118d1_8k.htm" ] }, "labelLink": { "local": [ "otlk-20230830_lab.xml" ] }, "presentationLink": { "local": [ "otlk-20230830_pre.xml" ] }, "schema": { "local": [ "otlk-20230830.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "otlk", "nsuri": "http://outlooktherapeutics.com/20230830", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2325118d1_8k.htm", "contextRef": "AsOf2023-08-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://outlooktherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2325118d1_8k.htm", "contextRef": "AsOf2023-08-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-096669-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-096669-xbrl.zip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end